Clinical pharmacology of midazolam in neonates and children: effect of disease-a review

Gian Maria Pacifici, Gian Maria Pacifici

Abstract

Midazolam is a benzodiazepine with rapid onset of action and short duration of effect. In healthy neonates the half-life (t 1/2) and the clearance (Cl) are 3.3-fold longer and 3.7-fold smaller, respectively, than in adults. The volume of distribution (Vd) is 1.1 L/kg both in neonates and adults. Midazolam is hydroxylated by CYP3A4 and CYP3A5; the activities of these enzymes surge in the liver in the first weeks of life and thus the metabolic rate of midazolam is lower in neonates than in adults. Midazolam acts as a sedative, as an antiepileptic, for those infants who are refractory to standard antiepileptic therapy, and as an anaesthetic. Information of midazolam as an anaesthetic in infants are very little. Midazolam is usually administered intravenously; when minimal sedation is required, intranasal administration of midazolam is employed. Disease affects the pharmacokinetics of midazolam in neonates; multiple organ failure reduces the Cl of midazolam and mechanical ventilation prolongs the t 1/2 of this drug. ECMO therapy increases t 1/2, Cl, and Vd of midazolam several times. The adverse effects of midazolam in neonates are scarce: pain, tenderness, and thrombophlebitis may occur. Respiratory depression and hypotension appear in a limited percentage of infants following intravenous infusion of midazolam. In conclusion, midazolam is a safe and effective drug which is employed as a sedative, as antiepileptic agent, for infants who are refractory to standard antiepileptic therapy, and as an anaesthetic.

References

    1. Neonatal Formulary. 6th edition. West Sussex, UK: John Wiley & Sons; 2011.
    1. De Wildt SN, Kearns GL, Sie SD, Hop WCJ, Van Den Anker JN. Pharmacodynamics of intravenous and oral midazolam in preterm infants. Clinical Drug Investigation. 2003;23(1):27–38.
    1. Young TE, Neofax MB. A Manual of Drugs Used in Neonatal Care. 23rd edition. Montvale, NJ, USA: Thomson Reuters; 2010.
    1. Mihi SJ, Harris RA. Hypnotic and sedatives. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman's. The Pharmacological Basis of Therapeutics. 12th edition. New York, NY, USA: McGraw Hill; 2011.
    1. Thummel KE, Shen DD. Isoherranen N. Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman's. The Pharmacological Basis of Therapeutics. 12th edition. New York, NY, USA: McGraw Hill; 2011.
    1. De Wildt SN, Kearns GL, Hop WCJ, Murry DJ, Abdel-Rahman SM, Van Den Anker JN. Pharmacokinetics and metabolism of oral midazolam in preterm infants. British Journal of Clinical Pharmacology. 2002;53(4):390–392.
    1. Oldenhof H, De Jong M, Steenhoek A, Janknegt R. Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? Clinical Pharmacology and Therapeutics. 1988;43(3):263–269.
    1. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. The New England Journal of Medicine. 2003;349(12):1157–1167.
    1. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver—evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. European Journal of Biochemistry. 1997;247(2):625–634.
    1. De Wildt SN, Kearns GL, Murry DJ, Koren G, Van Den Anker JN. Ontogeny of midazolam glucuronidation in preterm infants. European Journal of Clinical Pharmacology. 2010;66(2):165–170.
    1. Wrighton SA, Brian WR, Sari M-A, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3) Molecular Pharmacology. 1990;38(2):207–213.
    1. Mellon RD, Simone AF, Rappaport BA. Use of anesthetic agents in neonates and young children. Anesthesia and Analgesia. 2007;104(3):509–520.
    1. Jevtovic-Todorovic V, Hartman RE, Izumi Y, et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. Journal of Neuroscience. 2003;23(3):876–882.
    1. Young C, Jevtovic-Todorovic V, Qin Y-Q, et al. Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain. British Journal of Pharmacology. 2005;146(2):189–197.
    1. Ng E, Taddio A, Ohlsson A. Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit. Cochrane Database of Systematic Reviews. 2000;(2, article CD002052)
    1. Jacqz-Aigrain E, Daoud P, Burtin P, Desplanques L, Beaufils F. Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. The Lancet. 1994;344(8923):646–650.
    1. Hartwig S, Roth B, Theisohn M. Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit. European Journal of Pediatrics. 1991;150(11):784–788.
    1. Anand KJS, McIntosh N, Lagercrantz H, Pelausa E, Young TE, Vasa R. Analgesia and sedation in preterm neonates who require ventilatory support: results from the NOPAIN trial. Archives of Pediatrics and Adolescent Medicine. 1999;153(4):331–338.
    1. Arya V, Ramji S. Midazolam sedation in mechanically ventilated newborns: a double blind randomized placebo controlled trial. Indian Pediatrics. 2001;38(9):967–972.
    1. Lowrie L, Weiss AH, Lacombe C. The pediatric sedation unit: a mechanism for pediatric sedation. Pediatrics. 1998;102(3):p. E30.
    1. Ng E, Taddio A, Ohlsson A. Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit. Cochrane Database of Systematic Reviews. 2003;(1, article CD002052)
    1. Aranda JV, Carlo W, Hummel P, Thomas R, Lehr VT, Anand KJS. Analgesia and sedation during mechanical ventilation in neonates. Clinical Therapeutics. 2005;27(6):877–899.
    1. Hu K-C, Chiu N-C, Ho C-S, Lee S-T, Shen E-Y. Continuous midazolam infusion in the treatment of uncontrollable neonatal seizures. Acta Paediatrica Taiwanica. 2003;44(5):279–281.
    1. Castro Conde JR, Hernández Borges AA, Doménech Martínez E, González Campo C, Perera Soler R. Midazolam in neonatal seizures with no response to phenobarbital. Neurology. 2005;64(5):876–879.
    1. Malagon I, Hogenbirk K, van Pelt J, Hazekamp MG, Bovill JG. Effect of three different anaesthetic agents on the postoperative production of cardiac troponin T in paediatric cardiac surgery. British Journal of Anaesthesia. 2005;94(6):805–809.
    1. De Wildt SN, Kearns GL, Hop WCJ, Murry DJ, Abdel-Rahman SM, Van Den Anker JN. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clinical Pharmacology and Therapeutics. 2001;70(6):525–531.
    1. Vet NJ, Verlaat CWM, De Wildt SN, Tibboel D, De Hoog M. Daily interruption of sedation in critically ill children. Pediatric Critical Care Medicine. 2012;13(1, article 122)
    1. Jacqz-Aigrain E, Daoud P, Burtin P, Maherzi S, Beaufils F. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. European Journal of Clinical Pharmacology. 1992;42(3):329–332.
    1. Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. European Journal of Clinical Pharmacology. 1990;39(2):191–192.
    1. Mulla H, McCormack P, Lawson G, Firmin RK, Upton DR. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology. 2003;99(2):275–282.
    1. Ahsman MJ, Hanekamp M, Wildschut ED, Tibboel D, Mathot RAA. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clinical Pharmacokinetics. 2010;49(6):407–419.
    1. Burtin P, Jacqz-Aigrain E, Girard P, et al. Population pharmacokinetics of midazolam in neonates. Clinical Pharmacology and Therapeutics. 1994;56(6, part 1):615–625.
    1. Lee TC, Charles BG, Harte GJ, Gray PH, Steer PA, Flenady VJ. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. Anesthesiology. 1999;90(2):451–457.
    1. De Wildt SN, De Hoog M, Vinks AA, Van Der Giesen E, Van Den Anker JN. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Critical Care Medicine. 2003;31(7):1952–1958.
    1. Allegaert K, van den Anker JN, Naulaers G, de Hoon J. Determinants of drug metabolism in early neonatal life. Current Clinical Pharmacology. 2007;2(1):23–29.
    1. Ring JA, Ghabrial H, Ching MS, Smallwood RA, Morgan DJ. Fetal hepatic drug elimination. Pharmacology and Therapeutics. 1999;84(3):429–445.
    1. Ladona MG, Lindstrom B, Thyr C, Dun-Ren P, Rane A. Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. British Journal of Clinical Pharmacology. 1991;32(3):295–302.
    1. Gonzalez FJ, Coughtrie M, Tukey RH. Drug Metabolism. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman's. The Pharmacological Basis of Therapeutics. 12th edition. New York, NY, USA: McGraw Hill; 2011.
    1. Lee TC, Charles B. Measurement by HPLC of midazolam and its major metabolite, 1-hydroxymidazolam in plasma of very premature neonates. Biomedical Chromatography. 1996;10(2):65–68.
    1. Gorski JC, Hall SD, Jones DR, Van Den Branden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology. 1994;47(9):1643–1653.
    1. Wang RW, Newton DJ, Liu NY, Shou M, Rushmore T, Lu AYH. Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms. Drug Metabolism and Disposition. 1999;27(2):167–172.
    1. Keubler A, Weiss J, Haefeli WE, Mikus G, Burhenne J. Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1′-hydroxylation in vitro. Drug Metab Dispos. 2012;40(6):1178–1182.
    1. Ince I, de Wildt SN, Peeters MY, et al. mCritical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. Therapeutic Drug Monitoring. 2012;34(4):381–389.
    1. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994;4(4):171–184.
    1. Streetman DS, Bleakley JF, Kim JS, et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the &Cooperstown cocktail’. Clinical Pharmacology and Therapeutics. 2000;68(4):375–383.
    1. Ince I, de Wildt SN, Wang C, et al. A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults. Clinical Pharmacokinetics. 2013;52(7):555–565.
    1. Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology. 1985;62(3):310–324.
    1. Johnson TN, Tanner MS, Taylor CJ, Tucker GT. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. British Journal of Clinical Pharmacology. 2001;51(5):451–460.
    1. De Wildt SN, Kearns GL, Leeder JS, Van Den Anker JN. Cytochrome P450 3A. Ontogeny and drug disposition. Clinical Pharmacokinetics. 1999;37(6):485–505.
    1. Anderson BJ, Larsson P. A maturation model for midazolam clearance. Paediatric Anaesthesia. 2011;21(3):302–308.
    1. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. Journal of Pharmacokinetics and Biopharmaceutics. 1977;5(6):625–653.
    1. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metabolism and Disposition. 1997;25(9):1072–1080.
    1. Peeters MYM, Prins SA, Knibbe CAJ, et al. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology. 2006;105(6):1135–1146.
    1. De Wildt SN, De Hoog M, Vinks AA, Joosten KFM, Van Dijk M, Van Den Anker JN. Pharmacodynamics of midazolam in pediatric intensive care patients. Therapeutic Drug Monitoring. 2005;27(1):98–102.
    1. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clinical Pharmacokinetics. 2003;42(5):403–417.
    1. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. Journal of Critical Care. 2012;27(6):741.e9–741.e18.
    1. Mandema JW, Tuk B, Van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmcokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clinical Pharmacology and Therapeutics. 1992;51(6):715–728.
    1. Lloyd-Thomas AR, Booker PD. Infusion of midazolam in paediatric patients after cardiac surgery. British Journal of Anaesthesia. 1986;58(10):1109–1115.
    1. DeBerry BB, Lynch JE, Chernin JM, Zwischenberger JB, Chung DH. A survey for pain and sedation medications in pediatric patients during extracorporeal membrane oxygenation. Perfusion. 2005;20(3):139–143.
    1. Harrison AM, Davis S, Eggleston S, Cunningham R, Mee RBB, Bokesch PM. Serum creatinine and estimated creatinine clearance do not predict perioperatively measured creatinine clearance in neonates undergoing congenital heart surgery. Pediatric Critical Care Medicine. 2003;4(1):55–59.
    1. Hughes J, Gill AM, Mulhearn H, Powell E, Choonara I. Steady-state plasma concentrations of midazolam in critically ill infants and children. Annals of Pharmacotherapy. 1996;30(1):27–30.
    1. Mathews HML, Carson IW, Lyons SM, et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. British Journal of Anaesthesia. 1988;61(3):302–307.
    1. Swart EL, Slort PR, Plötz FB. Growing up with midazolam in the neonatal and pediatric intensive care. Current Drug Metabolism. 2012;13(6):760–766.
    1. Trouiller P, Fangio P, Paugam-Burtz C, et al. Frequency and clinical impact of preserved bispectral index activity during deep sedation in mechanically ventilated ICU patients. Intensive Care Medicine. 2009;35(12):2096–2104.
    1. Arbour R, Waterhouse J, Seckel MA, Bucher L. Correlation between the Sedation-Agitation Scale and the Bispectral Index in ventilated patients in the intensive care unit. Heart and Lung. 2009;38(4):336–345.
    1. Björkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. British Journal of Clinical Pharmacology. 2005;59(6):691–704.
    1. Björkman S. Prediction of cytochrome P450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clinical Pharmacokinetics. 2006;45(1):1–11.
    1. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clinical Pharmacokinetics. 2006;45(9):931–956.
    1. Marx CM, Smith PG, Lowrie LH, et al. Optimal sedation of mechanically ventilated pediatric critical care patients. Critical Care Medicine. 1994;22(1):163–170.
    1. Silvasi DL, Rosen DA, Rosen KR. Continuous intravenous midazolam infusion for sedation in the Pediatric Intensive Care Unit. Anesthesia and Analgesia. 1988;67(3):286–288.
    1. Rosen DA, Rosen KR. Midazolam for sedation in the paediatric intensive care unit. Intensive Care Medicine. 1991;17(supplement 1):S15–S19.
    1. Ancora G, Garetti E, Pirelli A, et al. Analgesic and sedative drugs in newborns requiring respiratory support. Journal of Maternal-Fetal and Neonatal Medicine. 2012;25(supplement 4):88–90.
    1. Rosen DA, Rosen KR. Intravenous conscious sedation with midazolam in paediatric patients. International Journal of Clinical Practice. 1998;52(1):46–50.
    1. American Academy of Pediatrics, Committee on Drugs. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics. 1992;89:1110–1115.
    1. Notterman DA. Sedation with intravenous midazolam in the pediatric intensive care unit. Clinical Pediatrics. 1997;36(8):449–454.
    1. Hughes J, Gill A, Leach HJ, et al. A prospective study of the adverse effects of midazolam on withdrawal in critically ill children. Acta Paediatrica, International Journal of Paediatrics. 1994;83(11):1194–1199.
    1. Treluyer J-M, Zohar S, Rey E, et al. Minimum effective dose of midazolam for sedation of mechanically ventilated neonates. Journal of Clinical Pharmacy and Therapeutics. 2005;30(5):479–485.
    1. Burtin P, Daoud P, Jacqz-Aigrain E, Mussat P, Moriette G. Hypotension with midazolam and fentanyl in the newborn. The Lancet. 1991;337(8756):1545–1546.
    1. Lazol JP, DeGroff CG. Minimal sedation second dose strategy with intranasal midazolam in an outpatient pediatric echocardiographic setting. Journal of the American Society of Echocardiography. 2009;22(4):383–387.
    1. Wilton NCT, Leight J, Rosen DR, Pandit UA. Preanesthetic sedation of preschool children using intranasal midazolam. Anesthesiology. 1988;69(6):972–975.
    1. Löwhagen P, Johansson BB, Nordborg C. The nasal route of cerebrospinal fluid drainage in man: a light-microscope study. Neuropathology and Applied Neurobiology. 1994;20(6):543–550.
    1. Berlin C.M. J, May-McCarver DG, Notterman DA, et al. Alternative routes of drug administration—advantages and disadvantages. Pediatrics. 1997;100(1):143–152.
    1. Knoester PD, Jonker DM, Van Der Hoeven RTM, et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. British Journal of Clinical Pharmacology. 2002;53(5):501–507.
    1. Burstein AH, Modica R, Hatton M, Forrest A, Gengo FM. Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. Journal of Clinical Pharmacology. 1997;37(8):711–718.
    1. Rey E, Delaunay L, Pons G, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. European Journal of Clinical Pharmacology. 1991;41(4):355–357.
    1. Ljungman G, Kreuger A, Andréasson S, Gordh T, Sörensen S. Midazolam nasal spray reduces procedural anxiety in children. Pediatrics. 2000;105(1, part 1):73–78.
    1. Griffith N, Howell S, Mason DG. Intranasal midazolam for premedication of children undergoing day-case anaesthesia: comparison of two delivery systems with assessment of intra-observer variability. British Journal of Anaesthesia. 1998;81(6):865–869.
    1. Kogan A, Katz J, Efrat R, Eidelman LA. Premedication with midazolam in young children: a comparison of four routes of administration. Paediatric Anaesthesia. 2002;12(8):685–689.
    1. Lane RD, Schunk JE. Atomized intranasal midazolam use for minor procedures in the pediatric emergency department. Pediatric Emergency Care. 2008;24(5):300–303.
    1. Harcke HT, Grissom LE, Meister MA. Sedation in pediatric imaging using intranasal midazolam. Pediatric Radiology. 1995;25(5):341–343.
    1. Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systematic review. Journal of Child Neurology. 2013;28(3):351–364.
    1. Sirsi D, Nangia S, LaMothe J, Kosofsky BE, Solomon GE. Successful management of refractory neonatal seizures with midazolam. Journal of Child Neurology. 2008;23(6):706–709.
    1. Eriksson M, Zetterstrom R. Neonatal convulsions. Incidence and causes in the Stockholm area. Acta Paediatrica Scandinavica. 1979;68(6):807–811.
    1. Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. The New England Journal of Medicine. 1999;341(7):485–489.
    1. Boylan GB, Rennie JM, Pressler RM, Wilson G, Morton M, Binnie CD. Phenobarbitone, neonatal seizures, and video-EEG. Archives of Disease in Childhood. 2002;86(3):F165–F170.
    1. Sheth RD, Buckley DJ, Gutierrez AR, Gingold M, Bodensteiner JB, Penney S. Midazolam in the treatment of refractory neonatal seizures. Clinical Neuropharmacology. 1996;19(2):165–170.
    1. van Rooij LG, Hellström-Westas L, de Vries LS. Treatment of neonatal seizures. Seminars in Fetal & Neonatal Medicine. 2013;18(4):209–215.
    1. Shany E, Benzaqen O, Watemberg N. Comparison of continuous drip of midazolam or lidocaine in the treatment of intractable neonatal seizures. Journal of Child Neurology. 2007;22(3):255–259.
    1. Yamamoto H, Aihara M, Niijima S, Yamanouchi H. Treatments with midazolam and lidocaine for status epilepticus in neonates. Brain and Development. 2007;29(9):559–564.
    1. Holmes GL, Riviello JJ., Jr. Midazolam and pentobarbital for refractory status epilepticus. Pediatric Neurology. 1999;20(4):259–264.
    1. Brevoord JCD, Joosten KFM, Arts WFM, van Rooij RW, de Hoog M. Status epilepticus: clinical analysis of a treatment protocol based on midazolam and phenytoin. Journal of Child Neurology. 2005;20(6):476–481.
    1. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Critical Care Medicine. 1992;20(4):483–488.
    1. Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. British Medical Journal. 2000;321(7253):83–86.
    1. Geldner G, Hubmann M, Knoll R, Jacobi K. Comparison between three transmucosal routes of administration of midazolam in children. Paediatric Anaesthesia. 1997;7(2):103–109.
    1. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. The Lancet. 2005;366(9481):205–210.
    1. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy and Behavior. 2004;5(2):253–255.
    1. Carbajal R, Eble B, Anand KJS. Premedication for tracheal intubation in neonates: confusion or controversy? Seminars in Perinatology. 2007;31(5):309–317.
    1. Penido MG, De Oliveira Silva DF, Tavares EC, E Silva YP. Propofol versus midazolam for intubating preterm neonates: a randomized controlled trial. Journal of Perinatology. 2011;31(5):356–360.
    1. Allegaert K, Peeters MY, Verbesselt R, et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. British Journal of Anaesthesia. 2007;99(6):864–870.
    1. Jobeir A, Galal MO, Bulbul ZR, Solymar L, Darwish A, Schmaltz AA. Use of low-dose ketamine and/or midazolam for pediatric cardiac catheterization: is an anesthesiologist needed? Pediatric Cardiology. 2003;24(3):236–243.
    1. Sweetman S, editor. Martindale: The Complete Drug Reference. 34th edition. London, UK: Pharmaceutical Press; 2005.
    1. Van den Anker JN, Sauer PJJ. The use of midazolam in the preterm neonate. European Journal of Pediatrics. 1992;151(2):p. 152.
    1. Sheridan RL, McEttrick M, Bacha G, Stoddard F, Tompkins RG. Midazolam infusion in pediatric patients with burns who are undergoing mechanical ventilation. Journal of Burn Care and Rehabilitation. 1994;15(6):515–518.
    1. Bergman I, Steeves M, Burckart G, Thompson A. Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration. Journal of Pediatrics. 1991;119(4):644–649.
    1. Vree TB, Shimoda M, Driessen JJ, et al. Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients. Clinical Pharmacology and Therapeutics. 1989;46(5):537–544.
    1. Harte GJ, Gray PH, Lee TC, Steer PA, Charles BG. Haemodynamic responses and population pharmacokinetics of midazolam following administration to ventilated, preterm neonates. Journal of Paediatrics and Child Health. 1997;33(4):335–338.
    1. Van Alfen-Van Der Velden AAEM, Hopman JCW, Klaessens JHGM, Feuth T, Sengers RCA, Liem KD. Effects of midazolam and morphine on cerebral oxygenation and hemodynamics in ventilated premature infants. Biology of the Neonate. 2006;90(3):197–202.
    1. Van Leuven K, Groenendaal F, Toet MC, et al. Midazolam and amplitude-integrated EEG in asphyxiated full-term neonates. Acta Paediatrica, International Journal of Paediatrics. 2004;93(9):1221–1227.
    1. Mulla H, Lawson G, Peek GJ, Firmin RK, Upton DR. Plasma concentrations of midazolam in neonates receiving extracorporeal membrane oxygenation. ASAIO Journal. 2003;49(1):41–47.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다